Compare Human Metabolome Technologies, Inc. with Similar Stocks
Dashboard
1
The company has declared positive results in Jun'2026 after 4 consecutive negative quarters
- NET SALES(Q) At JPY 314.75 MM has Grown at 66.86%
- NET PROFIT(Q) At JPY 34.64 MM has Grown at 167.1%
- RAW MATERIAL COST(Y) Fallen by -36.45% (YoY)
2
With ROE of 5.10%, it has a very expensive valuation with a 2.05 Price to Book Value
3
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
JPY 3,463 Million (Micro Cap)
40.00
NA
0.00%
-0.72
5.10%
1.84
Revenue and Profits:
Net Sales:
315 Million
(Quarterly Results - Jun 2026)
Net Profit:
35 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-3.03%
0%
-3.03%
6 Months
-13.98%
0%
-13.98%
1 Year
-17.59%
0%
-17.59%
2 Years
-1.14%
0%
-1.14%
3 Years
-15.3%
0%
-15.3%
4 Years
-30.48%
0%
-30.48%
5 Years
-28.86%
0%
-28.86%
Human Metabolome Technologies, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
4.27%
EBIT Growth (5y)
33.10%
EBIT to Interest (avg)
90.48
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.69
Sales to Capital Employed (avg)
0.68
Tax Ratio
9.19%
Dividend Payout Ratio
34.35%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
42.24%
ROE (avg)
11.07%
Valuation key factors
Factor
Value
P/E Ratio
40
Industry P/E
Price to Book Value
2.05
EV to EBIT
23.98
EV to EBITDA
11.57
EV to Capital Employed
4.72
EV to Sales
1.93
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
19.68%
ROE (Latest)
5.10%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'26 - YoY
Jun'26
Jun'25
Change(%)
Net Sales
314.80
188.60
66.91%
Operating Profit (PBDIT) excl Other Income
29.40
-75.80
138.79%
Interest
0.50
0.50
Exceptional Items
0.00
3.70
-100.00%
Consolidate Net Profit
34.60
-48.00
172.08%
Operating Profit Margin (Excl OI)
3.90%
-553.80%
55.77%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2026 is 66.91% vs -18.04% in Jun 2025
Consolidated Net Profit
YoY Growth in quarter ended Jun 2026 is 172.08% vs -426.53% in Jun 2025
Annual Results Snapshot (Consolidated) - Jun'26
Jun'26
Jun'25
Change(%)
Net Sales
1,421.90
1,455.00
-2.27%
Operating Profit (PBDIT) excl Other Income
321.30
353.30
-9.06%
Interest
2.00
2.50
-20.00%
Exceptional Items
18.00
28.80
-37.50%
Consolidate Net Profit
200.40
256.40
-21.84%
Operating Profit Margin (Excl OI)
147.60%
171.50%
-2.39%
USD in Million.
Net Sales
YoY Growth in year ended Jun 2026 is -2.27% vs 8.12% in Jun 2025
Consolidated Net Profit
YoY Growth in year ended Jun 2026 is -21.84% vs 5.43% in Jun 2025
About Human Metabolome Technologies, Inc. 
Human Metabolome Technologies, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available
Footer loading






